Asitalip Combo (Metformin Hydrochloride, Sitagliptin)

Asitalip Combo combines Metformin Hydrochloride and Sitagliptin for oral use, aiding in blood sugar management. This pharmaceutical is manufactured by Polfarmex S.A. in the EU.

Asitalip Combo is primarily used to help manage blood sugar levels in adults with type 2 diabetes. Metformin Hydrochloride works by reducing glucose production in the liver, while Sitagliptin enhances the body's natural insulin response. Together, they provide a comprehensive approach to blood sugar control. This combination is often prescribed when diet and exercise alone are not sufficient to manage blood sugar levels effectively.

Common effects of Asitalip Combo may include gastrointestinal discomfort, such as nausea or diarrhea, particularly when first starting the medication. Some users may also experience headaches or dizziness. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Asitalip Combo should be used with caution in individuals with kidney or liver issues. It is important to follow the prescribed dosage and not to adjust it without medical advice. Regular monitoring of blood sugar levels is recommended. Additionally, this medication should be stored at room temperature and kept out of reach of children.

Asitalip Combo may interact with certain medications, including other diabetes drugs, antibiotics, and some pain relievers. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be limited, as it can affect blood sugar levels and increase the risk of side effects.